Replimune (REPL) Preferred Stock Liabilities (2018)
Replimune's (REPL) quarterly Preferred Stock Liabilities came in at $86.4 million in Q2 2018, little changed quarter-over-quarter from $86.4 million in Q1 2018.
Replimune (REPL) Preferred Stock Liabilities (2018) Analysis & Trends
Replimune has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $86.4 million for Q2 2018.
- Preferred Stock Liabilities for Q2 2018 came in at $86.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $86.4 million (changed N/A YoY), and the FY2018 annual result was $86.4 million, up 173.22% from the prior year.
- Preferred Stock Liabilities came in at $86.4 million for Q2 2018 at Replimune, roughly flat from $86.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $86.4 million in Q1 2018 to a low of $86.4 million in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 86.36 Mn |
| Mar 31, 2018 | 86.36 Mn |